Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Other Solid Tumors

Interobserver Concordance Rates in Cancer Patients Imaged with CXCR4-directed PET/CT

Philipp Hartrampf, Aleksander Kosmala, Sebastian Serfling, Lena Bundschuh, Takahiro Higuchi, Constantin Lapa, Steven Rowe, Yohji Matsusaka, Alexander Weich, Andreas Buck, Ralph Bundschuh and Rudolf Werner
Journal of Nuclear Medicine June 2023, 64 (supplement 1) P15;
Philipp Hartrampf
1Department of Nuclear Medicine, University Hospital Wuerzburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aleksander Kosmala
2University Hospital Würzburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Serfling
2University Hospital Würzburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lena Bundschuh
3Nuclear Medicine, Medical Faculty, University Hospital Augsburg, Augsburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takahiro Higuchi
4Wurzburg Univ, ZIM A4
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Constantin Lapa
5University of Augsburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Rowe
6The Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yohji Matsusaka
7Department of Nuclear Medicine, University Hospital Würzburg, Würzburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Weich
8Internal Medicine II, Gastroenterology, University Hospital Würzburg, Würzburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Buck
9Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph Bundschuh
10Nuclear Medicine, Faculty of Medicine, University Hospital Augsburg, Augsburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rudolf Werner
9Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

P15

Introduction: C-X-C motif chemokine receptor 4 (CXCR4)-directed PET/CT has been utilized in recent years in varying tumor entities. Relative to other theranostic radiotracers, however, interobserver concordance rates for CXCR4-targeted imaging and therapy have not been provided yet.

Methods: In 50 cancer patients imaged with CXCR4-targeted PET/CT using [68Ga]PentixaFor, we evaluated interobserver agreement rates on a visual and quantitative level for imaging and therapy. In this regard, we evaluated scan results, CXCR4 density, number (No.) of affected organs and affected lymph node (LN) areas, as well as No. of organ and LN metastases. For quantification, readers identified target lesions (TL, for both LN and organ lesions). All readers also investigated whether patients would have been suitable for CXCR4-directed radioligand therapy (RLT). Intraclass correlation coefficients (ICCs) were interpreted in accordance to Cicchetti (0.4 - 0.59 fair, 0.6 - 0.74 good, 0.75 - 1, excellent agreement).

Results: For an overall scan results, fair concordance was recorded (ICC, 0.58). Moreover, good agreement was recorded as follows: No. of organ metastases (ICC, 0.74), CXCR4 density (ICC, 0.72), and No. of LN metastases (ICC, 0.65). Excellent concordance was then seen for No. of affected LN areas (ICC, 0.78) and affected organs (ICC, 0.76). For quantification, both organ and LN lesions also achieved excellent agreement rates with an ICC of minimum 0.92. When deciding on RLT, concordance was also excellent (ICC, 0.91).

Conclusions: Investigating patients scanned with [68Ga]PentixaFor PET/CT, we observed fair to excellent agreement rates for visual assessments. Excellent concordance was also recorded for quantification of TL and when to decide on patients eligible for CXCR4-RLT. Based on these favorable results, [68Ga]PentixaFor may be used more extensively in the clinic.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 64, Issue supplement 1
June 1, 2023
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Interobserver Concordance Rates in Cancer Patients Imaged with CXCR4-directed PET/CT
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Interobserver Concordance Rates in Cancer Patients Imaged with CXCR4-directed PET/CT
Philipp Hartrampf, Aleksander Kosmala, Sebastian Serfling, Lena Bundschuh, Takahiro Higuchi, Constantin Lapa, Steven Rowe, Yohji Matsusaka, Alexander Weich, Andreas Buck, Ralph Bundschuh, Rudolf Werner
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) P15;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Interobserver Concordance Rates in Cancer Patients Imaged with CXCR4-directed PET/CT
Philipp Hartrampf, Aleksander Kosmala, Sebastian Serfling, Lena Bundschuh, Takahiro Higuchi, Constantin Lapa, Steven Rowe, Yohji Matsusaka, Alexander Weich, Andreas Buck, Ralph Bundschuh, Rudolf Werner
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) P15;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Impact of dual tracer study to differentiate malignant vs benign peritoneal diseases.
  • Pediatric tumor patients scanned with a long axial field of view scanner – a single center experience on the use of lower administered doses of [18F]FDG
  • Radiation Absorbed Dose to Spinal Cord: Therapy of Leptomeningeal Metastasis Using Beta-Emission Radiopharmaceuticals
Show more Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Other Solid Tumors

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire